HCG Partners with Accenture to Revolutionize Cancer Research Using AI

HealthCare Global Enterprises Limited (HCG), India's largest cancer care network, is collaborating with Accenture to advance cancer research and care using cutting-edge AI technologies, including generative AI and deep learning. This initiative aims to harness multi-dimensional and multi-omic patient data to enable early detection and personalized treatment for various

Become a Member

Members have access to all articles.

Membership
cancers. Leveraging Accenture’s expertise in AI/ML, quantum computing, and generative AI, alongside HCG’s deep clinical insights, the program seeks to identify molecular alterations to improve patient care and outcomes. Initial efforts will focus on lung adenocarcinoma and head and neck cancers, with plans to extend the approach to other cancer types.

HCG, headquartered in Bengaluru, operates 22 comprehensive cancer centers across India and Africa, providing advanced diagnostic and therapeutic solutions. Accenture, a global leader in professional services and digital transformation, employs 774,000 people in over 120 countries and specializes in AI, cloud, and life sciences R&D. The partnership is expected to enhance precision medicine, optimize patient care, and accelerate research into new drug targets, biomarkers, and treatment pathways. According to HCG's Executive Chairman, B. S. Ajaikumar, this partnership emphasizes the role of AI in promoting patient-centric innovations. Senthil Ramani, Accenture's global lead of Data and AI, emphasized the transformative potential of generative AI in healthcare.

Read more

RELATED ARTICLESMORE FROM AUTHOR